<DOC>
	<DOCNO>NCT00542191</DOCNO>
	<brief_summary>This neoadjuvant chemotherapy protocol focus `` triple-negative '' breast cancer alone gather foundation primary tumor axillary lymph nodal response primary chemotherapy ongoing correlate disease-free ( DFS ) overall survival ( OS ) outcome data . This comparative data use building subsequent trial .</brief_summary>
	<brief_title>Phase II Trial Neoadjuvant Metronomic Chemotherapy Triple-Negative Breast Cancer</brief_title>
	<detailed_description>Women diagnose `` triple-negative '' proxy basal-like breast cancer confirm core biopsy large 2 cm treat neoadjuvantly Livingston metronomic regimen 12 week weekly doxorubicin 24 mg/m2 daily oral cyclophosphamide 60 mg/m2 follow 12 successive week taxol 80 mg/m2 carboplatin AUC 2 . Although clinical response evaluate prior surgery , primary end-point pathologic response . Secondary end-points DFS OS base upon standard care surveillance . A pathologic complete response ( pCR ) require histologic evidence residual malignant cell see primary tumor area specimen lymph node . Standard care surgery radiation therapy undertaken .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Women Estrogen Receptor ( ER ) , Progesterone Receptor ( PR ) , HER2 negative invasive breast cancer confirm core biopsy . ( Note : HER2 negative FISH prefer ; HER2 0 1+ IHC acceptable ) Primary tumor size 2cm great physical exam radiographic measurement . ( Note : Locally advance T4 inflammatory breast cancer eligible . ) Assessment pretreatment axillary lymph nodal status ( Note : FNA biopsy palpable sentinel lymph node biopsy ( SLNB ) palpable prefer ; clinical exam acceptable . ) Absolute neutrophil count &gt; 1500 mm3 platelet count &gt; 100,000 mm3 Normal myocardial leave ventricular function Serum creatinine &lt; 2.0 mg/dl Total bilirubin AST &lt; 3X upper limit normal Recurrent metastatic breast cancer finding ( Note : If oncologically felt second breast primary , patient eligible protocol ) Another active cancer present Medical contraindication chemotherapy surgery First trimester pregnancy Breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Triple negative ( ER/PR negative ; HER2 negative )</keyword>
</DOC>